Savara Inc. reported a net loss of $29.6 million, or $(0.14) per share, for the third quarter of 2025, compared with a net loss of $24.2 million, or $(0.11) per share, for the same period in 2024. Research and development expenses rose by 1.4% to $20.6 million, primarily due to activities related to the MOLBREEVI program. General and administrative expenses increased by 60.1% to $9.6 million, mainly due to higher personnel costs and commercial activities. As of September 30, 2025, Savara had cash, cash equivalents, and short-term investments of approximately $124.4 million and debt of about $29.8 million. The company recently raised about $140 million through an equity financing and announced a $75 million royalty funding agreement. Savara expects to resubmit the Biologics License Application for MOLBREEVI in December 2025 and to submit marketing authorization applications in Europe and the UK in the first quarter of 2026.